Linkedin17 Dec 2020 13:21
Chief Medical officer posted on Linkedin:
New CMC roles at Synairgen – an opportunity to support the development of a treatment for COVID-19
Following positive clinical trial results in a Phase II study in hospitalised COVID-19 patients, Synairgen (www.synairgen.com) is conducting a global Phase III trial with results expected 2021. Trials are also being performed in at-risk COVID-19 patients in the home setting. The drug, SNG001, interferon beta-1a nebuliser solution, is an inhaled broad-spectrum antiviral which has been shown to have clinical benefit in previous Phase II trials in patients with lung diseases with respiratory viral infections.
To support commercial manufacturing and a potential product launch next year, we are looking to recruit the following roles:
• Head of CMC
• Supply Chain and CDMO Manager
• Head of Regulatory and QA
For more information, please visit Synairgen’s website (https://lnkd.in/gR6Fynz).